Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.50 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568786 | 0.89 | PABPC1 (0.65) | MEN1KMT2ANOTUMMAPTALDH1A1 | |
| SCHEMBL6630687 | 0.86 | HSP90AA1 (0.56) | P2RY14MEN1KMT2ANOTUMTRPV1 | |
| SCHEMBL24969695 | 0.82 | ALDH1A1 (0.63) | MEN1KMT2ATRPV1MAPTALDH1A1 | |
| SCHEMBL30206829 | 0.82 | ALDH1A1 (0.63) | MEN1KMT2ATRPV1MAPTALDH1A1 | |
| SCHEMBL27528745 | 0.81 | MEN1 (0.63) | P2RY14MEN1KMT2ANOTUMTRPV1 | |
| SCHEMBL6363418 | 0.80 | MEN1 (0.70) | P2RY14MEN1KMT2ATRPV1PABPC1 | |
| SCHEMBL27389314 | 0.79 | MEN1 (0.76) | P2RY14MEN1KMT2ANOTUMTRPV1 | |
| SCHEMBL7101847 | 0.79 | PABPC1 (0.79) | MEN1KMT2ANOTUMTRPV1MAPT | |
| SCHEMBL28663512 | 0.78 | ALDH1A1 (0.69) | MEN1KMT2AMAPTALDH1A1PABPC1 | |
| SCHEMBL3310740 | 0.77 | MEN1 (0.63) | P2RY14MEN1KMT2ANOTUMTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014111871-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014111871-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-24 | — | — | WO | disclosed |
| EP-2307387-B1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8071586-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2307387-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010006938-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | P2RY14 183/4885MEN1 3301/4885KMT2A 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.